search
Back to results

A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN (AP-MPN)

Primary Purpose

Accelerated Phase MPN, Blast Phase MPN

Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
zelavespib
Sponsored by
Samus Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Accelerated Phase MPN focused on measuring myeloproliferative neoplasm

Eligibility Criteria

1 Year - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Able to provide signed informed consent and willing to comply with the requirements and restrictions listed in the informed consent form and in this protocol Aged ≥ 18 years Confirmed diagnosis of accelerated phase (10% to 19% blasts in peripheral blood or bone marrow) MPN arising on the background of previous PMF, PV, or ET Patients taking ruxolitinib must have been taking it for at least 3 months, with a stable dose at least 1 month before Cycle 1 Day 1 Eastern Cooperative Oncology Group (ECOG) performance status of 1 to 2 Acceptable organ function at screening, defined by the following criteria: absolute neutrophil count (ANC) ≥ 500/µL platelet count ≥ 50,000/µL alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2 × the upper limit of normal (ULN ) total serum bilirubin ≤ 1.5 × ULN creatinine clearance > 25 mL/min/1.73 m2 based on the Cockcroft-Gault equation Women of childbearing potential (defined as premenopausal or within 2 years of the onset of menopause, and not surgically sterile) must meet both the following criteria: negative urine or serum pregnancy test at screening and within 72 hours before the first dose of zelavespib agree to use one of the following acceptable method of highly effective contraception for the duration of the study and for 13 weeks after the final dose of study treatment Men must agree to the following requirements: a. men who are sexually active with women of childbearing potential must agree to the following requirements for the duration of their participation in the study and for 13 weeks after the final dose of study treatment: i. if the method of contraception is abstinence from penile vaginal intercourse as a usual and preferred lifestyle (abstinent on a long-term and persistent basis), men must agree to remain abstinent ii. if having penile vaginal intercourse with a nonpregnant, non-breastfeeding woman of childbearing potential, men must use a male condom, and their female partner must use a highly effective contraceptive method with a failure rate < 1% per year iii. men with a pregnant or breastfeeding partner must agree to remain abstinent from penile vaginal intercourse or use a male condom during each episode of penile penetration iv. men must refrain from donating sperm Exclusion Criteria: Known active liver disease, including viral hepatitis or cirrhosis Known or suspected infection with human immunodeficiency virus (HIV) or other active infection requiring acute or chronic treatment with systemic antibiotics (conditions requiring topical antibiotics are not exclusionary) Positive for HIV 1 or 2, hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibodies at screening Previous treatment with a hypomethylating agent Corrected QT interval using Fridericia's formula (QTcF) > 480 ms at screening or baseline ECG based on the median value of ECGs Personal or family history of long QT syndrome or taking any medication within 1 week or 5 half-lives (whichever is longer) before Cycle 1 Day 1 that carries a risk of Torsades de Pointes Left ventricular ejection fraction ≤ 50% or below the institution's lower limit of normal (whichever is lower) by echocardiogram or multigated acquisition (MUGA) scan Coronary artery disease with an ischemic event within 6 months before screening History of a second primary malignancy within 6 months before screening that requires treatment with systemic antineoplastic agents, except for the following, if appropriately treated and considered cured: Stage 1 endometrial cancer, surgically treated cervical or prostate carcinoma, and nonmelanoma skin cancer Note: Subjects who are receiving adjuvant or preventive therapy for indolent cancers may be eligible, and the investigator should discuss with the medical monitor. Any significant uncontrolled medical condition, as determined by the investigator, within 6 months before screening Planned use of antineoplastic agents (chemotherapy or cytotoxic drugs), immunotherapy, experimental therapy, or biologic therapy for treatment of MPN, with the exception of ruxolitinib Use of systemic corticosteroids (ie, prednisone > 20 mg/day or equivalent within 2 weeks before Cycle 1 Day 1 Planned or current use of strong cytochrome P450 (CYP)3A4/5, CYP2D6, or CYP2C19 inhibitors or inducers within 1 week or 5 half-lives (whichever is longer, for a maximum of 4 weeks) before Cycle 1 Day 1 Planned or current use of herbal preparations/medications within 7 days before Cycle 1 Day 1 Previous exposure to zelavespib (PU-H71) Uncontrolled diabetes mellitus, in the opinion of the investigator Any other condition or laboratory abnormality or receiving any other treatment that, in the opinion of the investigator, may increase the risk associated with study participation or that may interfere with interpretation of the study results Active ocular condition (eg, ocular inflammatory disease that, in the opinion of the investigator, may worsen during the course of the study, or a history or anticipation of major ocular surgery (eg, cataract extraction or other intraocular surgery) during the study Currently pregnant or breastfeeding, or planning to become pregnant History of gastrointestinal surgery or current gastrointestinal condition that could affect the absorption of oral medication

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Other

    Arm Label

    Oral zelavespib 100 mg

    Arm Description

    Oral zelavespib 100 mg will be administered once daily

    Outcomes

    Primary Outcome Measures

    Determine the MTD and safety of PU-H71 in subjects with AP-MPN and BP-MPN
    Assess the safety profile by measuring Incidence and severity of adverse events (AEs), changes in physical examinations, electrocardiograms (ECGs), vital signs, and clinical laboratory evaluations

    Secondary Outcome Measures

    Full Information

    First Posted
    October 4, 2021
    Last Updated
    November 4, 2022
    Sponsor
    Samus Therapeutics, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05612633
    Brief Title
    A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN
    Acronym
    AP-MPN
    Official Title
    A Phase 2 Open-label Study of Zelavespib (PU-H71) in Subjects With Accelerated Phase Myeloproliferative Neoplasm (AP MPN) or Blast Phase Myeloproliferative Neoplasm
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2022
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Samus Therapeutics Closure
    Study Start Date
    June 15, 2022 (Anticipated)
    Primary Completion Date
    December 15, 2023 (Anticipated)
    Study Completion Date
    February 23, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Samus Therapeutics, Inc.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is a multicenter, Phase 2 Simon 2-Stage study designed to assess the safety, tolerability, PK, and efficacy of oral zelavespib (PU-H71) administered daily in adults with accelerated phase (10% to 19% blasts in peripheral or bone marrow) myeloproliferative neoplasm, with or without ongoing concomitant treatment with ruxolitinib.
    Detailed Description
    Oral zelavespib 1501050 mg will be administered once daily (QD), in the morning ≥ 1 hour before eating breakfast, for each day of a 21-day cycle, for 6 cycles. Subjects who derive clinical benefit may continue treatment until disease progression, unacceptable toxicity, death, or study termination. In Stage 1, up to 2317 subjects will be enrolled and will complete 6 cycles of treatment. If fewer than 2 subjects achieve <CR?/PR?/CBR?/PBR?> in Stage 1, the trial will be stopped for futility. If 2 or more subjects achieve <CR?/PR?/CBR?/PBR?>a response , an additional 33 subjects will be enrolled, enrollment will begin in Stage 2 for a total of 56 subjects. . If fewer than 2 subjects achieve a response in Stage 1, the trial will be stopped for futility. In Cycle 1, subjects will attend 3 clinic visits (Day 1, Day 8, and Day 15) and will be contacted by phone by the site at approximately Day 4 . In subsequent cycles, subjects will attend a clinic visit on Day 1 onlyand will be contacted by phone on Days 8 and 15 so the site staff can inquire about changes in concomitant medications and potential AEs. On days of clinic visits, subjects will arrive at the clinic without eating anything in the morning or taking the study drug. Predose biological samples will be collected for safety laboratory tests and other clinical assessments, and subjects will undergo physical examinations and ECGs. Subjects will receive the study drug at the clinic and at least 1 hour after dosing, breakfast will be provided. On some clinic days, subjects may be required to remain in the clinic for up to 8 hours for additional ECGs and collection of samples for PK testing. Each subject will participate in the study for approximately 6.5 months , which includes a 28-day screening period, 6 cycles of treatment, and a final follow-up visit 30 days after the final dose of study treatment.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Accelerated Phase MPN, Blast Phase MPN
    Keywords
    myeloproliferative neoplasm

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Single Group Assignment
    Model Description
    In Stage 1, up to 2317 subjects will be enrolled and will complete 6 cycles of treatment. If fewer than 2 subjects achieve <CR?/PR?/CBR?/PBR?> in Stage 1, the trial will be stopped for futility. If 2 or more subjects achieve <CR?/PR?/CBR?/PBR?>a response , an additional 33 subjects will be enrolled, enrollment will begin in Stage 2 for a total of 56 subjects.
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Oral zelavespib 100 mg
    Arm Type
    Other
    Arm Description
    Oral zelavespib 100 mg will be administered once daily
    Intervention Type
    Drug
    Intervention Name(s)
    zelavespib
    Intervention Description
    Oral zelavespib 100 mg will be administered once daily
    Primary Outcome Measure Information:
    Title
    Determine the MTD and safety of PU-H71 in subjects with AP-MPN and BP-MPN
    Description
    Assess the safety profile by measuring Incidence and severity of adverse events (AEs), changes in physical examinations, electrocardiograms (ECGs), vital signs, and clinical laboratory evaluations
    Time Frame
    up to 6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    1 Year
    Maximum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Able to provide signed informed consent and willing to comply with the requirements and restrictions listed in the informed consent form and in this protocol Aged ≥ 18 years Confirmed diagnosis of accelerated phase (10% to 19% blasts in peripheral blood or bone marrow) MPN arising on the background of previous PMF, PV, or ET Patients taking ruxolitinib must have been taking it for at least 3 months, with a stable dose at least 1 month before Cycle 1 Day 1 Eastern Cooperative Oncology Group (ECOG) performance status of 1 to 2 Acceptable organ function at screening, defined by the following criteria: absolute neutrophil count (ANC) ≥ 500/µL platelet count ≥ 50,000/µL alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2 × the upper limit of normal (ULN ) total serum bilirubin ≤ 1.5 × ULN creatinine clearance > 25 mL/min/1.73 m2 based on the Cockcroft-Gault equation Women of childbearing potential (defined as premenopausal or within 2 years of the onset of menopause, and not surgically sterile) must meet both the following criteria: negative urine or serum pregnancy test at screening and within 72 hours before the first dose of zelavespib agree to use one of the following acceptable method of highly effective contraception for the duration of the study and for 13 weeks after the final dose of study treatment Men must agree to the following requirements: a. men who are sexually active with women of childbearing potential must agree to the following requirements for the duration of their participation in the study and for 13 weeks after the final dose of study treatment: i. if the method of contraception is abstinence from penile vaginal intercourse as a usual and preferred lifestyle (abstinent on a long-term and persistent basis), men must agree to remain abstinent ii. if having penile vaginal intercourse with a nonpregnant, non-breastfeeding woman of childbearing potential, men must use a male condom, and their female partner must use a highly effective contraceptive method with a failure rate < 1% per year iii. men with a pregnant or breastfeeding partner must agree to remain abstinent from penile vaginal intercourse or use a male condom during each episode of penile penetration iv. men must refrain from donating sperm Exclusion Criteria: Known active liver disease, including viral hepatitis or cirrhosis Known or suspected infection with human immunodeficiency virus (HIV) or other active infection requiring acute or chronic treatment with systemic antibiotics (conditions requiring topical antibiotics are not exclusionary) Positive for HIV 1 or 2, hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibodies at screening Previous treatment with a hypomethylating agent Corrected QT interval using Fridericia's formula (QTcF) > 480 ms at screening or baseline ECG based on the median value of ECGs Personal or family history of long QT syndrome or taking any medication within 1 week or 5 half-lives (whichever is longer) before Cycle 1 Day 1 that carries a risk of Torsades de Pointes Left ventricular ejection fraction ≤ 50% or below the institution's lower limit of normal (whichever is lower) by echocardiogram or multigated acquisition (MUGA) scan Coronary artery disease with an ischemic event within 6 months before screening History of a second primary malignancy within 6 months before screening that requires treatment with systemic antineoplastic agents, except for the following, if appropriately treated and considered cured: Stage 1 endometrial cancer, surgically treated cervical or prostate carcinoma, and nonmelanoma skin cancer Note: Subjects who are receiving adjuvant or preventive therapy for indolent cancers may be eligible, and the investigator should discuss with the medical monitor. Any significant uncontrolled medical condition, as determined by the investigator, within 6 months before screening Planned use of antineoplastic agents (chemotherapy or cytotoxic drugs), immunotherapy, experimental therapy, or biologic therapy for treatment of MPN, with the exception of ruxolitinib Use of systemic corticosteroids (ie, prednisone > 20 mg/day or equivalent within 2 weeks before Cycle 1 Day 1 Planned or current use of strong cytochrome P450 (CYP)3A4/5, CYP2D6, or CYP2C19 inhibitors or inducers within 1 week or 5 half-lives (whichever is longer, for a maximum of 4 weeks) before Cycle 1 Day 1 Planned or current use of herbal preparations/medications within 7 days before Cycle 1 Day 1 Previous exposure to zelavespib (PU-H71) Uncontrolled diabetes mellitus, in the opinion of the investigator Any other condition or laboratory abnormality or receiving any other treatment that, in the opinion of the investigator, may increase the risk associated with study participation or that may interfere with interpretation of the study results Active ocular condition (eg, ocular inflammatory disease that, in the opinion of the investigator, may worsen during the course of the study, or a history or anticipation of major ocular surgery (eg, cataract extraction or other intraocular surgery) during the study Currently pregnant or breastfeeding, or planning to become pregnant History of gastrointestinal surgery or current gastrointestinal condition that could affect the absorption of oral medication

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN

    We'll reach out to this number within 24 hrs